3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
27
Terminated
9
Unknown
6
Recruiting
3
Not yet recruiting
3
Active not recruiting
3
Withdrawn
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma
11
Small Cell Lung Carcinoma
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Follicular
5
Lung Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Carcinoma, Non-Small-Cell Lung
4
Burkitt Lymphoma
4
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large-Cell, Anaplastic
3
Hodgkin Disease
3
Waldenstrom Macroglobulinemia
2
Sarcoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, AIDS-Related
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoblastic Lymphadenopathy
2
Dendritic Cell Sarcoma, Interdigitating
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thymoma
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Sezary Syndrome
1
Interventions
Dexamethasone
14
Rituximab
6
Cytarabine
5
venetoclax
4
Lenalidomide
4
Bortezomib
4
Bendamustine Hydrochloride
4
selinexor
3
pomalidomide
3
pembrolizumab
3
ibrutinib
3
fludarabine
3
carfilzomib
3
Paclitaxel
3
Gemcitabine
3
Drug Therapy
3
Cyclophosphamide
3
Calcium Dobesilate
3
ixazomib
2
gilteritinib
2
fludarabine phosphate
2
elotuzumab
2
daratumumab
2
belinostat
2
Tablets
2
Surveys and Questionnaires
2
Panobinostat
2
Oxaliplatin
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Recurrence
×
Etoposide
×
Clear all
NCT00776802
2013-06-25
GCS-100LE
La Jolla Pharmaceutical Company
Phase 1/2
Withdrawn
NCT00801918
2013-05-15
Denileukine Diftitox for Relapsed ALCL
Columbia University
Phase 2
Withdrawn